Drugs Made In America Acquisition II Corp Unit
DMIIU
11 hedge funds and large institutions have $35M invested in Drugs Made In America Acquisition II Corp Unit in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
1.77% less ownership
Funds ownership: 8.5% → 6.73% (-1.8%)
19% less capital invested
Capital invested by funds: $43.5M → $35M (-$8.46M)
21% less funds holding
Funds holding: 14 → 11 (-3)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAL
TIG Advisors LLC
New York
|
-$5.02M |
| 2 |
KC
Kepos Capital
New York
|
-$2.11M |
| 3 |
CS
Clear Street
New York
|
-$1.6M |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
-$233K |
| 5 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
-$151K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $20.3M | – | – | – |
|
|
WCMNY
2
Westchester Capital Management (New York)
Valhalla,
New York
| $5.11M | – | – | – |
|
|
BCM
3
BlueCrest Capital Management
St Helier,
Jersey
| $2.54M | – | – | – |
|
4
Verition Fund Management
Greenwich,
Connecticut
| $2.54M | – | – | – |
|
|
LGM
5
L1 Global Manager
Melbourne,
| $1.02M | – | – | – |
|
|
RAM
6
Readystate Asset Management
Chicago,
Illinois
| $1.02M | – | – | – |
|
7
Walleye Capital
New York
| $1.02M | – | – | – |
|
|
HF
8
HRT Financial
New York
| $1.01M | -$2.78K | -275 | -0.3% |
|
|
RC
9
Rangeley Capital
New Canaan,
Connecticut
| $331K | -$233K | -23,061 | -41% |
|
|
CS
10
Clear Street
New York
| $82.1K | -$1.6M | -158,558 | -95% |
|
|
11
UBS Group
Zurich,
Switzerland
| $17.9K | +$20 | +2 | +0.1% |
|
|
TAL
12
TIG Advisors LLC
New York
| – | -$5.02M | -500,000 | Closed |
|
|
KC
13
Kepos Capital
New York
| – | -$2.11M | -210,000 | Closed |
|
|
RCM
14
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| – | -$151K | -15,000 | Closed |
|
DMIIU Hedge Fund Activity: Q2 2026 in Review
11 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Unit (DMIIU) for Q2 2026, worth a combined $35M — down 19% from $43.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DMIIU and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $20. The largest seller was TIG Advisors LLC, exiting entirely with an estimated $5.02M sold.
- 11 institutional investors held Drugs Made In America Acquisition II Corp Unit (DMIIU) as of Q2 2026, down from 14 in Q1 2026.
- Funds reported $35M of Drugs Made In America Acquisition II Corp Unit stock for Q2 2026, down 19% quarter-over-quarter.
- 0 funds opened new Drugs Made In America Acquisition II Corp Unit positions in Q2 2026 and 3 closed out, a net change of -3 holders.
- The largest Drugs Made In America Acquisition II Corp Unit buyer in Q2 2026 was UBS Group, an estimated $20 added.
- The largest Drugs Made In America Acquisition II Corp Unit seller in Q2 2026 was TIG Advisors LLC, an estimated $5.02M sold.
Based on aggregated 13F filings for Q2 2026.